Deals channel feed – Endpoints News

Deals channel feed

Buyout buzz bumps Madrigal stock further north, stoking the industry's NASH obsession

7 years ago

Top Celgene exec pins the blame for ozanimod fiasco on the Receptos team — acquired 3 years ago

7 years ago

Bitterly opposed old guard at Takeda wages a last-ditch fight to block 'foreign blood's' $62B Shire buyout

7 years ago

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

7 years ago

Merck data and a tumbling stock price cost Armo's investors $320M-plus in Eli Lilly buyout

7 years ago

Takeda bags $280M, sells off its stake in a China drug JV ahead of $62B Shire buyout

7 years ago

Will Shire's top R&D talent bolt now that Takeda has struck a merger agreement?

7 years ago

Vectalys and FlashCell merge into Flash Therapeutics, loaded with RNA pipeline and manufacturing set-up

7 years ago

Eli Lilly's oncology R&D spree continues with $576M deal to buy a startup and reel back Aurora A drug

7 years ago

Whisky, secrets, and code names: behind-the-scenes of Takeda's $62B Shire bid - Bloomberg

8 years ago

Playing catch-up, Eli Lilly swoops in with $1.6B cash deal for Armo Bio and its promising PhIII cancer drug

8 years ago

Takeda CEO Christophe Weber finally closes on his $62B deal to buy Shire — now he has to convince shareholders and slash jobs

8 years ago

Takeda closes in on a final $64B deal to buy Shire, starts to consider divestitures — reports

8 years ago

Playing the long game in I/O, J&J inks $1.04B deal to buy oncolytic virus platform biotech BeneVir

8 years ago

United Therapeutics bags rival SteadyMed for a bargain basement deal worth up to $216M, eliminating patent threat

8 years ago

What do you get when you integrate healthcare data from multiple sources into one comprehensive, global package? Travis May says he’s on track to find out

8 years ago

Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

8 years ago

Done deal? Takeda reaches a ‘breakthrough’ in Shire merger talks as deal announcement looms — Reuters

8 years ago

Shire says Takeda has come up with a new buyout offer as reports spotlight a looming handshake deal

8 years ago

Bankrupt and weary, diet pill maker Orexigen to sell for $75M to Nalpropion

8 years ago

After fruitless talks, a bid from Vas and plenty of patience, AveXis CEO Sean Nolan slowly reeled in an $8.7B deal

8 years ago

Pressing for direct negotiations, Takeda adds cash to a meatier $63B bid to buy Shire

8 years ago

On second thought, Allergan doesn't want to consider a bid for Shire, leaving Takeda in sole pursuit of $62.5B deal

8 years ago

Bidding war erupts for Shire as Takeda is stiff-armed on a $62.5B offer and Allergan jumps in

8 years ago

First page Previous page 107 108 109110111 112 113 Next page Last page